IP Library Granted Patent US 11,213,539
Granted Patent B2
US 11,213,539 · App. 15/777,102 · Granted Jan 4, 2022

Use of ivermectin and brimonidine in the treatment and/or prevention of moderate to severe rosacea

Inventors: Philippe Martel (Biot, FR); Nabil Kerrouche (Le Rouret, FR); Fabien Audibert (Roquette-sur-Siagne, FR)
Assignee: GALDERMA HOLDING SA
A61K31/7048A61K31/498A61P17/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,213,539
App. No.
15/777,102
Granted
Jan 4, 2022
Kind
B2
Abstract

The present invention relates to a combination of ivermectin and brimonidine for use in the treatment and/or the prevention of moderate to severe rosacea, preferably by topical administration of a 1% ivermectin cream and 0.33% brimonidine gel.

Claims (13)

1. A method of treating rosacea in a subject in need thereof, comprising topically administering, daily for at least 12 weeks:

(a) a composition comprising ivermectin in the form of a cream; and

(b) a composition comprising brimonidine or salts thereof in the form of a gel,

wherein:

ivermectin is present in an amount of between 0.75 and 1.5 percent by weight, relative to the total weight of the composition comprising ivermectin;

brimonidine or salts thereof are present in an amount of between 0.05 and 1 percent by weight, relative to the total weight of the composition comprising brimonidine; and

the ivermectin and brimonidine are present separately within distinct compositions.

2. The method of claim 1 , wherein ivermectin is present in an amount of 0.75, 1, or 1.5 percent by weight, relative to the total weight of the composition comprising ivermectin.

3. The method of claim 1 , wherein brimonidine or salts thereof are present in an amount of 0.33 percent by weight, relative to the total weight of the composition comprising brimonidine.

4. The method of claim 1 , wherein the composition comprising ivermectin is administered in the morning.

5. The method of claim 1 , wherein the composition comprising brimonidine is administered in the evening.

6. The method of claim 1 , wherein the composition comprising ivermectin is administered in the morning and the composition comprising brimonidine is administered in the evening.

7. The method of claim 1 , wherein the ivermectin is present at a concentration 1 percent by weight, relative to the total weight of the composition comprising ivermectin.

Assignments (4)
CHANGE OF ADDRESS Recorded Jun 28, 2022
From: GALDERMA HOLDING SA
To: GALDERMA HOLDING SA
Reel/Frame 060541/0374 →
CHANGE OF NAME Recorded Sep 28, 2021
From: NESTLÉ SKIN HEALTH S.A.
To: GALDERMA HOLDING SA
Reel/Frame 057630/0957 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2021
From: GALDERMA S.A.
To: NESTLÉ SKIN HEALTH S.A.
Reel/Frame 057652/0571 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2020
From: MARTEL, PHILIPPE; KERROUCHE, NABIL; AUDIBERT, FABIEN
To: GALDERMA S.A.
Reel/Frame 053393/0198 →
Priority Claims (1)
EP 15306822 · Nov 17, 2015 · regional
Continuity (1)
Related Publication 20180344757A1 · Dec 6, 2018